AAAAAA

   
Results: 1-10 |
Results: 10
CA 125 as a marker of tumor activity in advanced urothelial malignancy
Authors: Izes, JK Dyer, MW Callum, MG Bankes, P Libertino, JA McCaffrey, JA
Citation: Jk. Izes et al., CA 125 as a marker of tumor activity in advanced urothelial malignancy, J UROL, 165(6), 2001, pp. 1908-1913
Carcinoid tumor of the kidney - The use of somatostatin receptor scintigraphy in diagnosis and management
Authors: McCaffrey, JA Reuter, V Herr, HW Macapinlac, HA Russo, P Motzer, RJ
Citation: Ja. Mccaffrey et al., Carcinoid tumor of the kidney - The use of somatostatin receptor scintigraphy in diagnosis and management, UROL ONCOL, 5(3), 2000, pp. 108-111
Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer
Authors: Dodd, PM McCaffrey, JA Mazumdar, M Scher, H Higgins, G Boyle, MG Herr, H Bajorin, DF
Citation: Pm. Dodd et al., Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer, CANCER INV, 18(7), 2000, pp. 626-634
Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: Pattern and prognostic factors for relapse
Authors: Rabbani, F Sheinfeld, J Farivar-Mohseni, H Leon, A Rentzepis, MJ Reuter, VE Herr, HW McCaffrey, JA Motzer, RJ Bajorin, DF Bosl, GJ
Citation: F. Rabbani et al., Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: Pattern and prognostic factors for relapse, J CL ONCOL, 19(7), 2000, pp. 2020-2025
Phase I evaluation of sequential doxorubicin plus gemcitabine then ifosfamide plus paclitaxel plus cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract
Authors: Dodd, PM McCaffrey, JA Hilton, S Mazumdar, M Herr, H Kelly, WK Icasiano, E Boyle, MG Bajorin, DF
Citation: Pm. Dodd et al., Phase I evaluation of sequential doxorubicin plus gemcitabine then ifosfamide plus paclitaxel plus cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract, J CL ONCOL, 18(4), 2000, pp. 840-846
Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma
Authors: Dodd, PM McCaffrey, JA Mazumdar, M Icasiano, E Higgins, G Herr, H Bajorin, DF
Citation: Pm. Dodd et al., Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma, INV NEW DR, 18(3), 2000, pp. 247-251
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract - Final report of a phase II trial evaluating two dosing schedules
Authors: Bajorin, DF McCaffrey, JA Dodd, PM Hilton, S Mazumdar, M Kelly, WK Herrr, H Scher, HI Icasiano, E Higgins, G
Citation: Df. Bajorin et al., Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract - Final report of a phase II trial evaluating two dosing schedules, CANCER, 88(7), 2000, pp. 1671-1678
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma
Authors: Dodd, PM McCaffrey, JA Herr, H Mazumdar, M Bacik, J Higgins, G Boyle, MG Scher, HI Bajorin, DF
Citation: Pm. Dodd et al., Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma, J CL ONCOL, 17(8), 1999, pp. 2546-2552
Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
Authors: Bajorin, DF Dodd, PM Mazumdar, M Fazzari, M McCaffrey, JA Scher, HI Herr, H Higgins, G Boyle, MG
Citation: Df. Bajorin et al., Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy, J CL ONCOL, 17(10), 1999, pp. 3173-3181
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma
Authors: Dodd, PM McCaffrey, JA Mazumdar, M Scher, H Vlamis, V Higgins, G Herr, H Bajorin, DF
Citation: Pm. Dodd et al., Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma, CANCER, 85(5), 1999, pp. 1145-1150
Risultati: 1-10 |